Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CodaVax-H1N1 in healthy adults
NCT03926416Phase 1Completed
- Sponsor
- Codagenix
- Start
- Feb 2017
- Primary completion
- May 2018
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CodaVax-H1N1 in influenza (4 arms), sponsored by Codagenix. Primary endpoints: Number of subjects with solicited local and/or systemic reactions at 6 days, Incidence of Adverse Events (AE) at 30 days and 1 more. Started Feb 2017; status: completed.
02
Drugs
CodaVax-H1N1
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03926416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03926416.